A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy

Laura Orsolini; Silvia Bellagamba; Virginio Salvi; Umberto Volpe

doi:10.1016/j.ajp.2022.103121

A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy

Asian J Psychiatr. 2022 Jun:72:103121. doi: 10.1016/j.ajp.2022.103121. Epub 2022 Apr 9.

Authors

Laura Orsolini¹, Silvia Bellagamba², Virginio Salvi², Umberto Volpe²

Affiliations

¹ Unit of Clinical Psychiatry, Department of Neurosciences/DIMSC, School of Medicine and Surgery, Polytechnic University of Marche, Ancona, Italy. Electronic address: l.orsolini@staff.univpm.it.
² Unit of Clinical Psychiatry, Department of Neurosciences/DIMSC, School of Medicine and Surgery, Polytechnic University of Marche, Ancona, Italy.

PMID: 35427934
DOI: 10.1016/j.ajp.2022.103121

Abstract

Clozapine-resistant schizophrenia (CRS) occurs in 40%- 70% of clozapine-treated schizophrenic patients. Hereby we describe a 20-year-old CRS subject with comorbid cannabinoid use disorder, successfully treated with clozapine-brexpiprazole combination, subsequently switched to clozapine plus long-acting injectable aripiprazole.

Keywords: Brexpiprazole; Cannabinoid use disorder; Clozapine; Clozapine-treatment resistant schizophrenia; Schizophrenia.

Publication types

Case Reports

MeSH terms

Adult
Antipsychotic Agents* / adverse effects
Aripiprazole / adverse effects
Clozapine* / adverse effects
Drug Therapy, Combination
Humans
Quinolones
Schizophrenia* / drug therapy
Schizophrenia, Treatment-Resistant
Thiophenes
Young Adult

Substances

Antipsychotic Agents
Quinolones
Thiophenes
brexpiprazole
Aripiprazole
Clozapine